LQDA Liquidia Corporation

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference

MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, beginning at 3:45 p.m. ET in Boston.

Access to a webcast of the presentation will be available to investors and other interested parties by accessing Liquidia’s website at . An archived, recorded version of the presentation will be available on Liquidia’s website for at least 30 days following the event.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit .

Contact Information

Investors:

Jason Adair

Chief Business Officer

919.328.4350



Media:

Patrick Wallace

Director, Corporate Communications

919.328.4383



EN
27/08/2025

Underlying

LQDALiquidia Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Liquidia Corporation

 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Con...

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, beginning at 3:45 p.m. ET in Boston. Access to a webcast of the presentation will be available to investors and other interested parties by accessing Liquidia’s website at . An archived, recorded ver...

7h / 58m 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation Reports Second Quarter 2025 Financial Results and...

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA’s tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovativ...

August 12, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Report Second Quarter 2025 Financial Results o...

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at . A rebroadcast of the ...

August 5, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following...

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx) upon the U.S. District Court for the Middle District of North Carolina denying United Therapeutics Corporation’s request for a preli...

June 23, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostini...

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today anno...

June 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch